National Lipid Association

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings

Retrieved on: 
火曜日, 5月 21, 2024
Patient, Cardiovascular disease, Primate, EAS, Hypercholesterolemia, Risk, NLA, NAMS, Congress, Biomarker, Adipose tissue, National Lipid Association

NAARDEN, the Netherlands and MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present new clinical and preclinical data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 92nd Congress and the National Lipid Association (NLA) 2024 Scientific Sessions, taking place on May 26 – 29 in Lyon, France and May 30 – June 2 in Las Vegas, Nevada, respectively.

Key Points: 
  • -- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers --
    NAARDEN, the Netherlands and MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present new clinical and preclinical data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 92nd Congress and the National Lipid Association (NLA) 2024 Scientific Sessions, taking place on May 26 – 29 in Lyon, France and May 30 – June 2 in Las Vegas, Nevada, respectively.
  • Presentation details are as follows:
    Oral Presentation Session Date and Time: Monday, May 27, 2024, 2:42 PM- 2:49 PM CET (8:42 AM-8:49 AM ET)
    Oral Presentation Session Date and Time: Tuesday, May 28, 2024, 2:12 PM- 2:19 PM CET (8:12 AM-8:19 AM ET)
    Oral Presentation Session Date and Time: Tuesday, May 28, 2024, 3:17-3:24 CET (9:17 AM-9:24 AM ET)
    Oral Presentation Session Date and Time: Tuesday, May 28, 2024, 3:24-3:31 CET (9:24 AM-9:31 AM ET)
    Title: Obicetrapib does not Accumulate in Adipose Tissue: Results from Studies in Man and Non-Human Primates
    Title: Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates Abstract/Poster #: 127

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

Retrieved on: 
月曜日, 4月 29, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Bank of America, Congress, DEEP, ATS, Arrowhead, Antiviral Research, RESULTS, Conference, Asthma, EAS, NLA, National Lipid Association, AN, American Thoracic Society

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
    2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024
    BofA Securities 2024 Healthcare Conference – May 13-16, 2024
    TIDES USA 2024 – May 14-17, 2024
    American Thoracic Society (ATS) 2024 International Conference – May 17-22, 2024
    Title: A First-in-Human Study of ARO-RAGE, a Novel Inhaled RNA-Interference Therapy for Asthma
    37th International Conference on Antiviral Research (ICAR2024) – May 20-24, 2024
    European Atherosclerosis Society (EAS) 92nd Congress – May 26-29, 2024
    Title: PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
    Title: PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS
    Title: ZODASIRAN SILENCES HEPATIC ANGPTL3 LEADING TO DEEP AND DURABLE REDUCTIONS IN ATHEROGENIC LIPIDS AND LIPOPROTEINS IN MIXED DYSLIPIDEMIA PATIENTS: FINAL RESULTS FROM ARCHES-2, DOUBLE-BLIND PERIOD
    2024 National Lipid Association (NLA) Scientific Sessions – May 30 – June 2, 2024
    Title: ENCORE - PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
    Title: ENCORE - PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS
    Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Gaxos Health Forms Medical Advisory Board to Support Launch of AI-powered Health and Wellness Solution

Retrieved on: 
水曜日, 2月 28, 2024
Advisory board, Lipid, Weill Cornell Medicine, Intelligence, MD, Obesity, National Lipid Association, Cardiothoracic surgery, Hospital, Plaque, Hackensack University Medical Center, Yale University, Society, Helsinki University Central Hospital, Health, ASNC, American College, Internal medicine, Journal, Medicine, Medical Center, Research, Veterinary medicine

“The establishment of our Medical Advisory Board reflects our commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI.

Key Points: 
  • “The establishment of our Medical Advisory Board reflects our commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI.
  • He is an attending cardiologist at Hackensack University Medical Center’s Heart and Vascular Hospital where he is director of lipids and preventive cardiology.
  • Dr. Lebowitz received his MD from Cornell University Medical College (now Weill-Cornell Medical College) in New York.
  • “We welcome Dr. Lebowitz to the advisory board as his experience and talents will be invaluable to the creation of our solution,” Vadim Mats added.

Care Access Becomes Newest Member of the National Lipid Association Industry Council, Joining Novartis, Amgen, and Other Cardiovascular Health Leaders

Retrieved on: 
水曜日, 1月 31, 2024
Research, Surgery, Clinical Trials, Cardiology, Practice Management, Other Health, Health, General Health, Science, Principal, Stenosis, Physician, Novartis, National Lipid Association, Regeneron Pharmaceuticals, Clinical trial, Access, Cardiovascular disease, Patient, Esperion Therapeutics, Entrepreneurship, Therapy, Risk, NLA, Coronary artery disease, Learning, Stroke, Medicine, Amgen, Esperies, JD, Pharmaceutical industry

Care Access, a global clinical research company helping to accelerate the future of medicine, is joining the National Lipid Association (NLA) Industry Council.

Key Points: 
  • Care Access, a global clinical research company helping to accelerate the future of medicine, is joining the National Lipid Association (NLA) Industry Council.
  • The collaboration aims to enable more community-based lipidologists to participate in clinical research and create access to cardiometabolic trials for their patients.
  • The NLA represents doctors and other experts from around the country who treat patients at the highest risks of cardiovascular disease.
  • "At Care Access, we are committed to facilitating clinical trial access for patients from all walks of life," said Ahmad Namvargolian, Care Access CEO and Co-Founder.

Cardiometabolic Health Congress (CMHC) Launches Focused Digital Education Hubs

Retrieved on: 
木曜日, 7月 13, 2023
CME, Obesity, Pediatrics, Education, American Heart Association, Social, Catalog, National Lipid Association, Woman, Medicine, Risk, Spa, CHCP, CMHC, Student, Patient, News, Childhood Obesity (journal), Nursing

Previously, the education and resources on cardiometabolichealth.org were grouped only by format, such as CME courses, blogs, webinars, and expert interviews.

Key Points: 
  • Previously, the education and resources on cardiometabolichealth.org were grouped only by format, such as CME courses, blogs, webinars, and expert interviews.
  • These access points still exist for learners interested in certain formats rather than specific clinical topics, but are also available through the 12 focused education hubs.
  • They could find resources and education focused on that condition within both the Obesity Management and Pediatrics hubs.
  • The experts at CMHC are committed to creating education for practicing clinicians, students, and patients interested in the quickly evolving field of cardiometabolic health.

NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients

Retrieved on: 
月曜日, 6月 5, 2023
Dyslipidemia, Public, Cardiovascular disease, National Lipid Association, NAMS, Apolipoprotein, Osaka Medical and Pharmaceutical University, Ongo, Patient, China Pharmaceutical University, Moyamoya disease, Conference, Safety, Pharmaceutical industry

-- Management to Host Conference Call Today at 8:00 a.m. E.T. --

Key Points: 
  • Based on the results observed, NewAmsterdam plans to leverage data from the ongoing Phase 3 BROOKLYN, BROADWAY and PREVAIL clinical trials, if supportive, to pursue regulatory approval in Japan.
  • The Phase 2b trial was a placebo-controlled, double-blind, randomized, dose-finding trial to evaluate the efficacy, safety and tolerability of obicetrapib as an adjunct to stable statin therapy in Japanese patients.
  • NewAmsterdam anticipates sharing full data from this Phase 2b clinical trial in a forthcoming publication or in a presentation at an upcoming medical meeting.
  • ET to review these data, as well as the full data from the Phase 2 ROSE2 clinical trial, which were presented on Saturday.

NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

Retrieved on: 
土曜日, 6月 3, 2023
Consensus, Journal of Clinical Lipidology, Therapy, Cardiovascular Research, Ezetimibe, Cardiovascular disease, Clinical trial, National Lipid Association, Baylor University, NAMS, Apolipoprotein, Low-density lipoprotein, Journal, Patient, Risk, LDL, Baylor College of Medicine, Apolipoprotein B, Hand, Conference, Pharmaceutical industry

ROSE2 met its primary and secondary endpoints, with statistically significant and clinically meaningful reductions in LDL-C and apolipoprotein B (“ApoB”) observed.

Key Points: 
  • ROSE2 met its primary and secondary endpoints, with statistically significant and clinically meaningful reductions in LDL-C and apolipoprotein B (“ApoB”) observed.
  • In addition, the combination of obicetrapib and ezetimibe was observed to be well-tolerated, with a safety profile observed to be comparable to placebo.
  • “The data presented today are highly encouraging, showing that the combination of obicetrapib and ezetimibe delivers robust impacts on multiple atherogenic lipid parameters.
  • The table below shows the median percent change from baseline in patients receiving the combination of obicetrapib and ezetimibe, obicetrapib monotherapy and placebo.

NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023

Retrieved on: 
火曜日, 5月 23, 2023
High, Ezetimibe, Icahn School of Medicine at Mount Sinai, National Lipid Association, NAMS, Research, Mount Sinai, Pharmaceutical industry, Patient

NewAmsterdam is developing a fixed dose combination of obicetrapib 10 mg and ezetimibe 10 mg, and expects to select a formulation to advance into a definitive bioequivalence trial and a Phase 3 safety and efficacy trial in the second half of 2023.

Key Points: 
  • NewAmsterdam is developing a fixed dose combination of obicetrapib 10 mg and ezetimibe 10 mg, and expects to select a formulation to advance into a definitive bioequivalence trial and a Phase 3 safety and efficacy trial in the second half of 2023.
  • Details of the presentation are as follows:
    Presentation Title: The combination of Obicetrapib and Ezetimibe lowers LDL-C in Patients on High Intensity Statins: Results from the ROSE2 Trial (NCT05266586)
    NewAmsterdam will host a conference call for investors and analysts to review the full data from ROSE2.
  • While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.
  • A live webcast of the call will also be available under “Events & Presentations” in the Investors & News section of the Company’s website at https://ir.newamsterdampharma.com .

The Inner Circle Acknowledges, Kenneth Bescak, MD, F.A.C.C., as a Distinguished Top Pinnacle Professional for his contributions to the Medical Field

Retrieved on: 
金曜日, 5月 19, 2023
Verde Valley, Ohio State University, Heart failure, Internal medicine, American Heart Association, Cardiac rehabilitation, American College of Cardiology, American Board of Internal Medicine, Cardiovascular disease, National Lipid Association, Multimedia, Private practice, Inner circle, Heart Failure Society of America, American College of Physicians, American Board of Commissioners for Foreign Missions, Patient, Cardiology, American College of Chest Physicians, American College, Medical specialty, Raffles Medical Group, Medical device, Physician, MD, Cottonwood

COTTONWOOD, Ariz., May 18, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Kenneth Bescak, MD, F.A.C.C., is acknowledged as a Top Pinnacle Professional for his contributions to the Medical Field.

Key Points: 
  • COTTONWOOD, Ariz., May 18, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Kenneth Bescak, MD, F.A.C.C., is acknowledged as a Top Pinnacle Professional for his contributions to the Medical Field.
  • Dr. Bescak began his medical educational journey from Ohio State University, Columbus where he received his medical degree.
  • An exemplary diagnostic cardiologist, Dr. Bescak is one of only 500 board-certified lipidologists in the U.S. and one of only seven in Arizona.
  • He was also honored as a distinguished Fellow of the American College of Cardiology and the American College of Chest Physicians.

NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
金曜日, 3月 31, 2023
Apolipoprotein AI, Dyslipidemia, Apolipoprotein E, Frazier Healthcare Partners, PIPE, National Lipid Association, NAMS, Research, Apolipoprotein, History, Cerebrospinal fluid, Sale, Development, Hospital, Acquisition, Patient, CETP, Administration, Pivotal, Science, FLAC, ASCVD, Moyamoya disease, NLA, Pharmaceutical industry, Cryptocurrency, Ezetimibe, Menarini

NAARDEN, The Netherlands and MIAMI, March 31, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced its financial results for the full year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • “2022 was a transformative year for NewAmsterdam, and we are thrilled to have achieved significant corporate and clinical milestones that have propelled our company forward.
  • In January 2023, NewAmsterdam announced topline results from ROSE2, a Phase 2 clinical trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy.
  • In October 2022, NewAmsterdam initiated a Phase 2 dose-finding study of obicetrapib as an adjunct to stable statin therapy in Japanese patients with dyslipidemia.
  • Cash Position: As of December 31, 2022, NewAmsterdam had cash of €439 million, compared to €53 million as of December 31, 2021.